Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Almirall ( (ES:ALM) ) is now available.
Almirall reported total assets of €2.56 billion at 31 December 2025, slightly down from €2.59 billion a year earlier, reflecting a modest decrease in its balance sheet size. Non‑current assets declined mainly due to lower investments in group companies and associates, although intangible assets and property, plant and equipment increased, signaling continued investment in core operations.
Current assets also eased to €597 million from €611 million, with reductions in cash and cash equivalents partly offset by higher inventories and current accruals. The stable asset mix, with a strong base of intangibles and intra‑group investments, suggests Almirall is maintaining its strategic focus on proprietary products and group structure while managing liquidity more tightly going into 2026.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a Spanish pharmaceutical company based in Barcelona, focused on developing and commercializing medicines, particularly in specialty therapeutic areas. The company operates globally, investing in intangible assets such as product rights and R&D, and maintains significant holdings in group companies and associates as part of its long‑term strategy.
Average Trading Volume: 200,021
Technical Sentiment Signal: Buy
Current Market Cap: €2.97B
See more insights into ALM stock on TipRanks’ Stock Analysis page.